Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

A Distinct Oncogenerative Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity.

Díaz-Carballo D, Saka S, Klein J, Rennkamp T, Acikelli AH, Malak S, Jastrow H, Wennemuth G, Tempfer C, Schmitz I, Tannapfel A, Strumberg D.

Cancer Res. 2018 May 1;78(9):2318-2331. doi: 10.1158/0008-5472.CAN-17-1861. Epub 2018 Feb 12.

PMID:
29440172
2.

Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cells.

Díaz-Carballo D, Klein J, Acikelli AH, Wilk C, Saka S, Jastrow H, Wennemuth G, Dammann P, Giger-Pabst U, Khosrawipour V, Rassow J, Nienen M, Strumberg D.

Oncotarget. 2017 Oct 7;8(56):95945-95964. doi: 10.18632/oncotarget.21606. eCollection 2017 Nov 10.

3.

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.

Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, De Dosso S, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D.

Ann Oncol. 2017 Oct 1;28(10):2429-2435. doi: 10.1093/annonc/mdx343.

PMID:
28961832
4.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

5.

Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.

Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J.

Cancer Lett. 2016 Oct 28;381(2):296-304. doi: 10.1016/j.canlet.2016.08.007. Epub 2016 Aug 11.

PMID:
27524505
6.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.

Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA.

J Gastrointest Surg. 2016 Feb;20(2):367-73. doi: 10.1007/s11605-015-2995-9. Epub 2015 Oct 28.

7.

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.

Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA.

Colorectal Dis. 2016 Apr;18(4):364-71. doi: 10.1111/codi.13130.

PMID:
26400556
8.

Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements.

Díaz-Carballo D, Acikelli AH, Klein J, Jastrow H, Dammann P, Wyganowski T, Guemues C, Gustmann S, Bardenheuer W, Malak S, Tefett NS, Khosrawipour V, Giger-Pabst U, Tannapfel A, Strumberg D.

J Exp Clin Cancer Res. 2015 Aug 12;34:81. doi: 10.1186/s13046-015-0199-5.

9.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.

Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25.

PMID:
25818084
10.

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O, Lange C, Giese K, Kaufmann J, Khan M, Drevs J.

J Clin Oncol. 2014 Dec 20;32(36):4141-8. doi: 10.1200/JCO.2013.55.0376. Epub 2014 Nov 17.

PMID:
25403217
11.

Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation.

Díaz-Carballo D, Gustmann S, Jastrow H, Acikelli AH, Dammann P, Klein J, Dembinski U, Bardenheuer W, Malak S, Araúzo-Bravo MJ, Schultheis B, Aldinger C, Strumberg D.

DNA Cell Biol. 2014 Nov;33(11):749-74. doi: 10.1089/dna.2014.2375. Epub 2014 Aug 15.

12.

Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells.

Díaz-Carballo D, Acikelli AH, Bardenheuer W, Gustmann S, Malak S, Stoll R, Kedziorski T, Nazif MA, Jastrow H, Wennemuth G, Dammann P, Feigel M, Strumberg D.

Int J Clin Pharmacol Ther. 2014 Sep;52(9):787-801. doi: 10.5414/CP202154.

PMID:
24902844
13.

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):642-52. doi: 10.5414/CP202109.

PMID:
24800922
14.

Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.

Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, Strumberg D, Reymond MA.

Gynecol Oncol. 2014 Feb;132(2):307-11. doi: 10.1016/j.ygyno.2013.11.022. Epub 2013 Nov 23.

PMID:
24275155
15.

Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.

Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, Zieren J, Schwab M, Reymond MA.

Ann Surg Oncol. 2014 Feb;21(2):553-9. doi: 10.1245/s10434-013-3213-1. Epub 2013 Sep 5.

16.

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB.

Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13.

17.

A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.

Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E.

J Cardiovasc Pharmacol. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff.

PMID:
23429593
18.

Sarcomatoid non-small cell lung cancer responding to sunitinib.

Schultheis B, Kummer G, Strumberg D.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):87-8. No abstract available.

19.

Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity.

Díaz-Carballo D, Gustmann S, Acikelli AH, Bardenheuer W, Klein J, Dembinski U, Kohl B, Yip KT, Nazif A, Stoll R, Strumberg D.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):54-5. No abstract available.

PMID:
23260000
20.

Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines.

Acikelli AH, Gustmann S, Bardenheuer W, Klein J, Dembinski U, Kohl B, Yip KT, Nazif A, Stoll R, Strumberg D, Díaz-Carballo D.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):51-3. No abstract available.

21.

7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells.

Díaz-Carballo D, Gustmann S, Acikelli AH, Bardenheuer W, Buehler H, Jastrow H, Ergun S, Strumberg D.

Phytomedicine. 2012 Nov 15;19(14):1298-306. doi: 10.1016/j.phymed.2012.08.004. Epub 2012 Sep 14.

PMID:
22981203
22.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

23.

Regorafenib for cancer.

Strumberg D, Schultheis B.

Expert Opin Investig Drugs. 2012 Jun;21(6):879-89. doi: 10.1517/13543784.2012.684752. Review.

PMID:
22577890
24.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K.

Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8.

25.

Sorafenib for the treatment of renal cancer.

Strumberg D.

Expert Opin Pharmacother. 2012 Feb;13(3):407-19. doi: 10.1517/14656566.2012.654776. Epub 2012 Jan 20. Review.

PMID:
22263843
26.

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group.

Lancet Oncol. 2012 Feb;13(2):135-44. doi: 10.1016/S1470-2045(11)70397-7. Epub 2012 Jan 17.

PMID:
22257523
27.

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, Giese K, Kaufmann J, Drevs J.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):76-8. No abstract available.

28.

Angioimmunoblastic T-cell lymphoma, combined with antiphospholipid syndrome and autoimmune thrombocytopenia (case report).

Schultheis B, Kummer G, Riebeling J, Strumberg D.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):74-5. No abstract available.

29.

Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.

Schultheis B, Neumann H, Roy R, Heuer V, Kummer G, Strumberg D.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):72-3. No abstract available.

30.

Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.

Scheulen ME, Saito K, Hilger RA, Mende B, Zergebel C, Strumberg D.

Cancer Chemother Pharmacol. 2012 Mar;69(3):753-61. doi: 10.1007/s00280-011-1761-2. Epub 2011 Oct 22.

PMID:
22020317
31.

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.

Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J.

Invest New Drugs. 2012 Oct;30(5):1962-71. doi: 10.1007/s10637-011-9754-x. Epub 2011 Oct 12.

PMID:
21989836
32.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, Büchert M, Krätzschmer J, Delesen H, Rajagopalan P, Christensen O.

Vasc Cell. 2011 Jul 29;3:16. doi: 10.1186/2045-824X-3-16.

33.

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.

Schultheis B, Kummer G, Zeth M, Brendel E, Xia C, Kornacker M, Strumberg D.

Cancer Chemother Pharmacol. 2012 Feb;69(2):333-9. doi: 10.1007/s00280-011-1685-x. Epub 2011 Jul 8.

PMID:
21735354
34.

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).

Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME.

Invest New Drugs. 2012 Jun;30(3):1184-92. doi: 10.1007/s10637-011-9665-x. Epub 2011 Apr 12.

PMID:
21484249
35.

A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

Mross K, Büchert M, Fasol U, Jaehde U, Kanefendt F, Strumberg D, Arends J, Hense J, Moritz B, Fischer R, Scheulen ME.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):96-8. No abstract available.

PMID:
21176744
36.

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt F, Lindauer A, Kinzig M, Strumberg D, Scheulen ME, Mross K, Fischer R, Moritz B, Sörgel F, Jaehde U.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):88-90. No abstract available.

PMID:
21176741
37.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.

PMID:
21170759
38.

Observation of de novo bladder dysfunction under treatment with Her2-neu antibodies.

Hinkel A, Strumberg D, Noldus J, Pannek J.

Urol Int. 2011;86(1):80-4. doi: 10.1159/000317441. Epub 2010 Nov 27.

PMID:
21109724
39.

Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis.

Díaz-Carballo D, Ueberla K, Kleff V, Ergun S, Malak S, Freistuehler M, Somogyi S, Kücherer C, Bardenheuer W, Strumberg D.

Int J Clin Pharmacol Ther. 2010 Oct;48(10):670-7.

PMID:
20875373
40.

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.

von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators.

Ann Oncol. 2011 Feb;22(2):301-6. doi: 10.1093/annonc/mdq350. Epub 2010 Jul 12.

PMID:
20624784
41.

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5. No abstract available.

PMID:
20557849
42.

First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).

Strumberg D, Bergmann L, Graeven U, Hanauske A, Lipp R, Schuette J, Schultheis B, Scigalla P, Urrea P, Scheulen ME.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):470-2. No abstract available.

PMID:
20557848
43.

Successful sequential antiangiogenic therapy for alveolar soft part sarcoma - a case report.

Schultheis B, Kummer G, Tannapfel A, Strumberg D.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):468-9. No abstract available.

PMID:
20557847
44.

Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.

Schultheis B, Riebeling J, Allali M, Bergmann U, Kummer G, Sendler U, Tannapfel A, Sendler A, Strumberg D.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):451-2. No abstract available.

PMID:
20557841
45.

Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.

Kirchner H, Strumberg D, Bahl A, Overkamp F.

Expert Rev Anticancer Ther. 2010 Apr;10(4):585-96. doi: 10.1586/era.10.25. Review.

PMID:
20397923
46.

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

Schlüter B, Gerhards R, Strumberg D, Voigtmann R.

J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.

PMID:
20217132
47.

Acquired resistance to cytostatics triggers cancer stem-cell-like phenotype in different tumor entities.

Díaz-Carballo D, Acikelli AH, Gustmann S, Bardenheuer W, Strumberg D.

J Stem Cells Regen Med. 2010 Oct 23;6(2):146-7. eCollection 2010. No abstract available.

PMID:
24693154
48.

Pharmacokinetic study of S-1.

Mende B, Krauss J, Thyssen D, Kredtke S, Scheulen ME, Strumberg D, Hanauske A, Makris L, Scigalla P, Urrea PD, Hilger RA.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):65-7. No abstract available.

PMID:
19203542
49.

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D.

Eur J Cancer. 2009 Mar;45(4):579-87. doi: 10.1016/j.ejca.2008.10.039. Epub 2008 Dec 26.

PMID:
19101137
50.

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K.

Br J Cancer. 2008 Nov 18;99(10):1579-85. doi: 10.1038/sj.bjc.6604724.

Supplemental Content

Loading ...
Support Center